New indications for treatment of chronic inflammation by TNF-α blockade
NM Kaplan, BF Palmer, AM Reimold - The American Journal of the Medical …, 2003 - Elsevier
The impressive anti-inflammatory effects of the tumor necrosis factor (TNF) α blockers
etanercept and infliximab have led to their use in multiple inflammatory diseases besides
their original indication, rheumatoid arthritis (RA). The well-studied clinical effects of both
agents in RA are the reduction of signs and symptoms of joint inflammation as well as the
arrest of bone destruction. Infliximab has also been Food and Drug Administration-approved
in the treatment of Crohn disease; etanercept is now FDA-approved for juvenile chronic …
etanercept and infliximab have led to their use in multiple inflammatory diseases besides
their original indication, rheumatoid arthritis (RA). The well-studied clinical effects of both
agents in RA are the reduction of signs and symptoms of joint inflammation as well as the
arrest of bone destruction. Infliximab has also been Food and Drug Administration-approved
in the treatment of Crohn disease; etanercept is now FDA-approved for juvenile chronic …